Skip Navigation
Search Menu
Find an Expert


Ronan Joseph Kelly, M.B.A., M.B.B.Ch., M.D.

Photo of Dr. Ronan Joseph Kelly, M.B.A., M.B.B.Ch., M.D.

Associate Professor of Oncology


Expertise: Esophageal Cancer, Gastroesophageal Cancer, Medical Oncology, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Stomach Cancer, Thymic Carcinoma, Thymoma more

Request an Appointment

I live in Maryland

Request an appointment through MyChart!

I live outside of Maryland

Request Appointment

I live outside of the United States

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 443-287-0005



  • Associate Professor of Oncology



  • MB BCH BAO, Royal College of Surgeons in Ireland (1998)


  • Beaumont Hospital / Internal Medicine (2000)
  • Mater Misericordiae University Hospital / Internal Medicine (2004)


  • Waterford Regional Hospital / Medical Oncology (2005)
  • Beaumont Hospital / Medical Oncology (2006)
  • Tallaght Hospital / AMNCH / Medical Oncology (2007)
  • National Cancer Institute-Oncology / Medical Oncology (2011)

Research & Publications

Selected Publications

1. Evaluation of KRAS mutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib. Kelly RJ, Rajan A, Force J, Keen C, Cao L, Yu Y, Choyke PL, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Lopez-Chavez A, Kummar S, Guttierrez M, Giaccone G. Clin Cancer Res. 2011 Mar 1;17(5):1190-9. Epub 2011 Jan 11
2. A pharmacodynamic study of docetaxel in combination with the p-glycoprotein (Pgp) antagonist, tariquidar (XR9576) in patients with lung, ovarian and cervical cancer. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. Clin Cancer Res. 2011 Feb 1;17(3):569-580.
3. A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas. Arun Rajan*, Ronan J. Kelly*, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, William D. Figg, Brett E.Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone. (*co-first authors). Clin Cancer Res. 2011 Nov 1;17(21):6831-9.
4. Thymic Malignancies From Clinical Management To Targeted Development. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. J Clin Oncol. 2011 Dec 20, 29(36):4820-7.
5. Belinostat phase II study in patients with recurrent or refractory advanced thymic epithelial tumors. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee M, Cao L, Espinoza-Delgado I, Spittler J, Loehrer P. J Clin Oncol. 2011 May 20;29(15):2052-9. Epub 2011 Apr 18.
6. A Phase 1 study of the chimeric anti-mesothelin monoclonal antibody MORAB 009 in patients with mesothelin expressing cancers. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Clin Cancer Res. 2010 Dec 15;16(24):6132-6138.
7. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. Kelly RJ, Carter C, Giaccone G. J Clin Oncol. 2010 Oct 1;28(28):e507-10.
8. Targeting the immune system in non small cell lung cancer - bridging the gap between promising concept and therapeutic reality. Kelly RJ, Gulley J, Giaccone G. Clinical Lung Cancer. 2010 Jul 1;11(4):228-37.
9. Chemotherapy and targeted therapy for unresectable malignant mesothelioma. Kelly RJ, Sharon E, Hassan R. Lung Cancer. 2011 Sep; 73(3):256-63. Epub 2011 May 28.
10. The role of Talactoferrin Alfa in non small cell lung cancer. Kelly RJ, Giaccone G. Expert Opin Biol Ther. 2010 Sep;10(9):1379-86.
11. Thymoma associated paraneoplastic polymyositis. Kelly RJ, S Browne, Rajan A, Giaccone G. J Clin Oncol. 2010 Aug 1;28(22):e378.
Is this you? Edit Profile